Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Standard BioTools Inc. (NASDAQ: LAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about its analytical laboratory instrument manufacturing business, which focuses on SomaScan, mass cytometry and microfluidics technologies used in proteomics and genomics research.
Current reports on Form 8-K are particularly important for tracking material events at Standard BioTools. Recent 8-K filings describe quarterly financial results, including revenue from continuing operations and segment performance, as well as operational restructuring plans involving reductions in force and the consolidation of South San Francisco-based R&D into the company’s Singapore facility. Other 8-Ks detail governance and compensation matters, such as changes to equity incentive plans and retention awards for senior executives.
A key filing for LAB is the Form 8-K describing the Stock Purchase Agreement with Illumina, Inc., under which Illumina will acquire SomaLogic, Inc. and related entities that operate Standard BioTools’ aptamer-based and functional proteomics business. This filing outlines the transaction structure, cash consideration, potential earnouts and royalty arrangements, and the fact that the company’s mass cytometry and microfluidics businesses are being retained.
On Stock Titan, these SEC filings are updated from EDGAR and paired with AI-powered summaries that highlight the main points, such as changes in revenue outlook, restructuring costs, or the terms of significant transactions. Users can quickly identify items related to results of operations, exit or disposal activities, and material definitive agreements, and then drill into the full text of each filing for deeper analysis of LAB’s financial condition, strategic direction and corporate governance.
Standard BioTools Inc. files its annual report describing a life sciences tools business focused on proteomics and genomics platforms, including CyTOF, Hyperion and Biomark systems. The company sold its SomaScan proteomics subsidiaries to Illumina under a Stock Purchase Agreement signed June 22, 2025, with the transaction closing January 30, 2026, and now reports those operations as discontinued.
For 2025, it highlights a more than $70 billion addressable market in life science research tools and notes that $56.9 million, or 67% of total revenue, came from customers outside the United States. Standard BioTools reports a 2025 net loss of $74.9 million and an accumulated deficit of $1.3 billion as of December 31, 2025, while emphasizing ongoing restructuring and cost actions.
The company details competitive dynamics against major life science tool providers, dependence on key suppliers, extensive global regulatory and data-privacy obligations, and numerous risk factors ranging from market volatility and acquisitions to litigation related to its merger with SomaLogic. As of March 12, 2026, it had 390,071,506 common shares outstanding, 389 employees worldwide, and a non‑affiliate equity market value of approximately $290.9 million as of June 30, 2025.
Casdin Eli reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director and 10% owner Eli Casdin received 52,991 restricted stock units on the company’s common stock at $1.17 per share equivalent. The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service. Casdin elected to receive these RSUs instead of $62,000 in cash compensation for board work. After this grant, he directly holds 2,954,053 common shares or equivalents, and investment funds associated with him hold additional indirect positions through Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund, L.P., and Casdin Partners Master Fund, L.P.
Cox Troy reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director Troy Cox reported an award of 57,264 restricted stock units representing common stock on February 26, 2026. These RSUs were valued at $1.17 per share for reporting purposes and bring his directly held stake to 376,586 shares after the grant.
The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service through each vesting date. Cox elected to receive this equity grant instead of $67,000 in cash compensation for his board role.
Carey Thomas D. reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director Thomas D. Carey received a grant of 51,282 shares of common stock in the form of restricted stock units valued at $1.17 per share. These RSUs were taken in lieu of $60,000 in cash board compensation and will vest in four equal quarterly installments during 2026, subject to his continued service. Following this grant, his directly held common stock totals 245,340 shares.
STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a Form 4 showing a tax-related share disposition. On the transaction date, 66,127 shares of common stock were withheld at $1.15 per share to cover tax withholding obligations from vesting restricted stock units. After this tax-withholding disposition, Egholm directly owned 5,551,710 shares of common stock.
STANDARD BIOTOOLS INC. executive Sean Mackay, SVP & Chief Business Officer, reported a tax-related share disposition. On February 23, 2026, 19,661 shares of common stock were withheld at $1.15 per share to cover tax obligations from previously granted restricted stock units that vested. After this withholding, Mackay directly holds 760,174 shares of Standard BioTools common stock. This was a tax-withholding disposition, not an open-market purchase or sale.
STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 12,740 shares of common stock at $1.15 per share to cover tax obligations. After this withholding, Kim directly owns 2,407,346 common shares, which includes 5,000 shares acquired on November 28, 2025 under the employee stock purchase plan.
Standard BioTools Inc. reported fourth-quarter 2025 revenue from continuing operations of $23.8 million and full-year 2025 revenue of $85.3 million, both down modestly year over year. Despite lower sales, gross margin improved to 47.8% for the quarter and 49.9% for the year, helped by mix and efficiency gains.
Operating expenses fell 11% in 2025 to $152.8 million as the company fully operationalized over $40 million of annualized cost savings. Net loss from continuing operations narrowed to $58.8 million, aided by a $38.4 million non-cash tax valuation allowance release. Cash, cash equivalents and liquid investments were $210.7 million at year-end, and management cited approximately $550 million in cash and investments after the January 30, 2026 SomaLogic transaction. For 2026, the company guides revenue to $80–$85 million, with seasonality similar to prior years.
Standard BioTools Inc. filed an amended report to add unaudited pro forma financial statements reflecting the completed sale of its SomaScan business (SomaLogic and Sengenics entities) to Illumina. The company received approximately $363.7 million in net cash proceeds at closing and recognized a pro forma gain on sale of about $161.9 million, strengthening its cash position. It also became eligible for up to $75 million in additional earnout payments tied to SomaScan-related revenues in fiscal 2025 and 2026, plus a 2% royalty on SOMAmer-based NGS library prep kit revenues for 10 years and a co-exclusive IP license for certain Single SOMAmer assays. Pro forma 2024 results remove the disposed operations, reducing reported revenue but narrowing net loss attributable to common stockholders from $184.9 million to $133.8 million.
Standard BioTools has completed the previously announced sale of all equity interests in SomaLogic, Inc. and related Sengenics entities to Illumina, divesting its aptamer-based and functional proteomics business. Illumina agreed to pay up to $425 million in cash, including an upfront $350 million at closing and up to $75 million in earnout payments tied to specified revenue targets for SOMAmer-based products in fiscal years 2025 and 2026.
The company is retaining its mass cytometry and microfluidics businesses. As additional consideration, Standard BioTools will receive specified royalty streams on net revenues from SOMAmer-based next-generation sequencing library preparation kits and from Single SOMAmers, and it obtained a license to Single SOMAmer intellectual property for potential singleplex affinity assays. A transition services agreement will support Illumina’s operation of the divested business. Following the transaction, Standard BioTools and its subsidiaries will no longer receive payments under SomaLogic’s collaboration agreement with Illumina Cambridge.